Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Regulators

European Medicines Agency head steps down after “procedural error”

The move follows an appeal made by Emil Hristov, a Bulgarian drug regulator who applied for the top job but was unsuccessful.

A “procedural error” has led to the annulment of Guido Rasi’s appointment to the position of executive director of the European Medicines Agency in 2011

Source: European Medicines Agency

Guido Rasi has been forced to step down from his position as the executive director of the European Medicines Agency

Guido Rasi, the executive director of the European Medicines Agency (EMA), has been forced to step down after a “procedural error” in the process that appointed him to the position. 

Bulgarian drug regulator Emil Hristov, who applied for the job but was unsuccessful, appealed to the European Union Civil Service Tribunal. He alleged that the European Commission did not follow procedure when it drew up its shortlist of candidates for the executive director’s appointment, on which he did not appear. 

The tribunal, announcing its judgment on 13 November 2014, agreed with Hristov. It annulled the European Commission’s shortlist decision and, as a consequence, the appointment of Rasi on “purely formal grounds”. 

Sir Kent Woods, chairman of the EMA management board, said: “It is important to remember that the ruling is about a procedural formality. It is not a reflection on Rasi’s competence or ability to run the agency, something which he has done successfully since November 2011.” 

EMA deputy executive director Andreas Pott has taken charge of the agency with immediate effect while the European Commission and the EMA seek legal advice. The EMA would not comment on the consequences for Rasi of any further legal decisions.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067165

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.